Akili, Inc., a digital medicine company, develops digital therapeutics for cognitive impairments. It provides EndeavorRx, a physician-prescribed video game-based treatment designed to directly target cognitive functioning. The company is based in Boston, Massachusetts.
According to Akili, Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 0.65. At the end of 2022 the company had a P/B ratio of 0.30.
Year | P/B ratio |
---|---|
2023 | 0.65 |
2022 | 0.30 |
2021 | 4.82 |
2020 | -7.50 |
2019 | -9.57 |